Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7878)	6/26/2000 12:54:00 PM
From: Jim Oravetz	Respond to of 8116

Cytogen Corp. (CYTO) submitted a regulatory dossier to the European Agency for the Evaluation of Medicinal Products for marketing approval of ProstaScint, a monoclonal antibody for the imaging of metastatic prostate cancer. In a press release Monday, Cytogen said it would have the right to market the product in the 15-country European Union if it received approval. The company also would be able to seek expedited marketing approval in Central and Eastern European countries and other non-EU nations that belong to the European Economic Area. Biopharmaceutical company Cytogen has been selling ProstaScint since 1997 in the U.S.